SEC Tracker
Get the app
TXG · XBRL financial data

10x Genomics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (TXG's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers154184*141153152165*155173149166*151151
Cost of revenue5868*48494554*49484953*4539
Gross profit96116*93104106111*105125100113*106112
Selling, general and administrative8286*86838294*90747577*6679
Total operating expenses190171*154146148161*14595133133*123132
Operating income (loss)(95)(55)*(61)(42)(41)(50)*(39)30(32)(20)*(17)(20)
Interest income45*5554*4457*55
Interest expense00*0000*00(0)0*—0
Other income (expense)(1)4*(1)(0)2(3)*23(1)(3)*(1)(4)
Income tax expense (benefit)12*2111*12(1)1*1(1)
Net income (loss)(93)(49)*(60)(38)(36)(49)*(34)35(27)(16)*(13)(18)
Earnings per share, basic USD per share(0.79)(0.41)*(0.50)(0.32)(0.30)(0.40)*(0.28)0.28(0.22)(0.13)*(0.10)(0.14)
Earnings per share, diluted USD per share(0.79)(0.41)*(0.50)(0.32)(0.30)(0.40)*(0.28)0.28(0.22)(0.13)*(0.10)(0.14)
Weighted average shares, basic millions of shares118119*119120121122*123124126127*128130
Weighted average shares, diluted millions of shares118119*119120121122*123125126126*128130

Balance sheet

CSV

Fiscal quarters (TXG's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents315359356380398344377398433474490503
Marketable securities4629160049505050495050
Accounts receivable10411591918488535044473948
Inventory817483889483756962565353
Prepaid and other current assets201921201820262019222019
Total current assets562596567579594584580656660684670675
Property and equipment, net285280269263259253246240233227221215
Right-of-use asset696563616057566364605857
Goodwill555555555557
Total assets9499659239309389199039801,0271,0411,0161,030
Accounts payable191620212613101618131721
Total current liabilities105127109111121118108112147153114119
Lease liability, non-current888481797673717776737067
Total liabilities203224204206215209196207242245201205
Accumulated deficit(1,235)(1,284)(1,344)(1,382)(1,418)(1,467)(1,501)(1,467)(1,494)(1,511)(1,524)(1,542)
Total stockholders' equity745741719724723710707773785796814826
Total liabilities and equity9499659239309389199039801,0271,0411,0161,030
Common shares outstanding (cover page) millions of shares—119———122———128——

Cash flows

CSV

Fiscal quarters (TXG's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(93)(49)*(60)(38)(36)(49)*(34)35(27)(16)*(13)(18)
Stock-based compensation40*39*3638*34*33*3128*25*25*2326*
Depreciation and amortization9*10*99*9*9*88*10*10*1010*
Net cash from operating activities(25)*26*(16)7*22*(7)*3418*43*41*2617*
Purchases of property and equipment15*3*33*4*3*22*1*2*22*
Net cash from investing activities5*13*1112*(4)*(52)*(2)(1)*(9)*(2)*(1)(8)*
Net cash from financing activities4*6*25*0*5*04*1*2*(8)3*
Net change in cash(16)*45*(4)24*18*(54)*3321*35*41*1612*

Compare with peers

SIC 3826 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3826 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
10x Genomics50315117*not reported— 10-QJun 30, 2026
Cohu2721735.6*47.3M— 10-QSep 26, 2026
Aehr Test Systems11619*1.8*32.6M— 10-KMay 29, 2026
Transcat6.7938.89.4M— 10-QJun 27, 2026
EyePoint1100.5(62)*86.2M2.9 quarters 10-QJun 30, 2026
Ralliant271568106*110.6M— 10-QJul 3, 2026
Allient4215414*17.0M— 10-QJun 30, 2026
Bruker185839(77)*152.4M2.4 quarters 10-QJun 30, 2026
Sensata Technologies Holding5531,004225*145.6M— 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.